THIRD AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT dated as of February 13, 2012 among VALEANT PHARMACEUTICALS INTERNATIONAL, INC., as Borrower, CERTAIN SUBSIDIARIES OF VALEANT PHARMACEUTICALS INTERNATIONAL, INC., as Guarantors, VARIOUS LENDERS...Credit and Guaranty Agreement • February 17th, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
This THIRD AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT, dated as of February 13, 2012, is entered into by and among VALEANT PHARMACEUTICALS INTERNATIONAL, INC., a corporation continued under the federal laws of Canada (“Borrower”), CERTAIN SUBSIDIARIES OF BORROWER, as Guarantors, the Lenders party hereto from time to time, GOLDMAN SACHS LENDING PARTNERS LLC (“GSLP”), J.P. MORGAN SECURITIES LLC (“J.P. Morgan”) and MORGAN STANLEY SENIOR FUNDING, INC. (“Morgan Stanley”), as Joint Lead Arrangers and Joint Bookrunners, JPMORGAN CHASE BANK, N.A. and Morgan Stanley as Co-Syndication Agents (in such capacity, the “Co-Syndication Agents”), JPMorgan Chase Bank, N.A., as Issuing Bank, GSLP, as Administrative Agent (together with its permitted successors in such capacity, “Administrative Agent”) and as Collateral Agent (together with its permitted successors in such capacity, “Collateral Agent”), and RBC CAPITAL MARKETS and DNB BANK ASA, as Co-Documentation Agents (in such capacity, Co-Docu
SECOND SUPPLEMENTAL INDENTURESupplemental Indenture • February 17th, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
SECOND SUPPLEMENTAL INDENTURE, dated as of February 13, 2012 (the “Second Supplemental Indenture”), by and among Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), Valeant Holdco 2 Pty Ltd., (ACN 154 341 367) (“Valeant Holdco”), Wirra Holdings Pty Limited, (ACN 122 216 577) (“Wirra Holdings”), Wirra Operations Pty Limited, (ACN 122 250 088) (“Wirra Operations”), iNova Pharmaceuticals (Australia) Pty Ltd., (ACN 000 222 408) (“iNova Pharmaceuticals”), iNova Sub Pty Ltd., (ACN 134 398 815)(“iNova Sub”) and Wirra IP Pty Ltd., (ACN 122 536 350) (“Wirra IP” and, together with Valeant Holdco, Wirra Holdings, Wirra Operations, iNova Pharmaceuticals and iNova Sub, the “New Guarantors”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
FOURTH SUPPLEMENTAL INDENTURESupplemental Indenture • February 17th, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
FOURTH SUPPLEMENTAL INDENTURE, dated as of February 13, 2012 (the “Fourth Supplemental Indenture”), by and among Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), Valeant Holdco 2 Pty Ltd., (ACN 154 341 367) (“Valeant Holdco”), Wirra Holdings Pty Limited, (ACN 122 216 577) (“Wirra Holdings”), Wirra Operations Pty Limited, (ACN 122 250 088) (“Wirra Operations”), iNova Pharmaceuticals (Australia) Pty Ltd., (ACN 000 222 408) (“iNova Pharmaceuticals”), iNova Sub Pty Ltd., (ACN 134 398 815)(“iNova Sub”) and Wirra IP Pty Ltd., (ACN 122 536 350) (“Wirra IP” and, together with Valeant Holdco, Wirra Holdings, Wirra Operations, iNova Pharmaceuticals and iNova Sub, the “New Guarantors”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENTCredit and Guaranty Agreement • February 17th, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
This AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED CREDIT AND GUARANTY AGREEMENT, dated as of February 13, 2012 (this “Amendment No. 1”), is made in reference to the Second Amended and Restated Credit and Guaranty Agreement, dated as of October 20, 2011, by and among VALEANT PHARMACEUTICALS INTERNATIONAL, INC., a corporation continued under the federal laws of Canada (“Borrower”), certain Subsidiaries of Borrower, as Guarantors, Goldman Sachs Lending Partners LLC, as administrative agent (in such capacity, the “Administrative Agent”), swing line lender and collateral agent (in such capacity, the “Collateral Agent”) and the lenders party thereto (the “Existing Lenders”) (as amended by the Joinder Agreement dated as of December 19, 2011, the “Existing Credit Agreement”). All capitalized terms not otherwise defined in this Amendment No. 1 have the same meanings as specified in the Credit Agreement (as defined in Section 1 below).
THIRD SUPPLEMENTAL INDENTURESupplemental Indenture • February 17th, 2012 • Valeant Pharmaceuticals International, Inc. • Pharmaceutical preparations • New York
THIRD SUPPLEMENTAL INDENTURE, dated as of February 13, 2012 (the “Third Supplemental Indenture”), by and among Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), Valeant Holdco 2 Pty Ltd., (ACN 154 341 367) (“Valeant Holdco”), Wirra Holdings Pty Limited, (ACN 122 216 577) (“Wirra Holdings”), Wirra Operations Pty Limited, (ACN 122 250 088) (“Wirra Operations”), iNova Pharmaceuticals (Australia) Pty Ltd., (ACN 000 222 408) (“iNova Pharmaceuticals”), iNova Sub Pty Ltd., (ACN 134 398 815)(“iNova Sub”) and Wirra IP Pty Ltd., (ACN 122 536 350) (“Wirra IP” and, together with Valeant Holdco, Wirra Holdings, Wirra Operations, iNova Pharmaceuticals and iNova Sub, the “New Guarantors”), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the “Trustee”).
